Biological Availability

"Biological Availability" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.

Descriptor ID	D001682
MeSH Number(s)	G03.787.151 G07.690.725.129
Concept/Terms	Biological Availability Biological Availability Availability, Biological Availabilities, Biological Biological Availabilities Biologic Availability Physiologic Availability Availability, Biologic Availabilities, Biologic Biologic Availabilities Bioavailability Bioavailabilities Availability, Physiologic Availabilities, Physiologic Physiologic Availabilities Availability Equivalency Availability Equivalency Availability Equivalencies Equivalencies, Availability Equivalency, Availability

Below are MeSH descriptors whose meaning is more general than "Biological Availability".

Biological Sciences [G]
Metabolism [G03]
Pharmacokinetics [G03.787]
Biological Availability [G03.787.151]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Pharmacokinetics [G07.690.725]
Biological Availability [G07.690.725.129]

Below are MeSH descriptors whose meaning is related to "Biological Availability".

Below are MeSH descriptors whose meaning is more specific than "Biological Availability".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Biological Availability" by people in this website by year, and whether "Biological Availability" was a major or minor topic of these publications.

Bar chart showing 64 publications over 24 distinct years, with a maximum of 8 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	2	2
2000	0	2	2
2001	0	5	5
2002	0	2	2
2003	0	4	4
2004	0	1	1
2005	0	1	1
2006	0	1	1
2007	0	2	2
2008	0	7	7
2010	0	3	3
2012	0	1	1
2013	0	3	3
2014	0	3	3
2015	0	3	3
2016	0	3	3
2017	0	1	1
2018	0	5	5
2019	0	1	1
2020	0	2	2
2021	0	8	8
2022	0	2	2
2023	0	1	1
2024	1	0	1

Below are the most recent publications written about "Biological Availability" by people in Profiles.

Bagde A, Mosley-Kellum K, Spencer S, Singh M. 3D DLP-printed cannabinoid microneedles patch and its pharmacokinetic evaluation in rats. J Pharm Pharmacol. 2024 Jun 06; 76(6):616-626.

View in: PubMed
Zeamer AL, Salive MC, An X, Beaudoin FL, House SL, Stevens JS, Zeng D, Neylan TC, Clifford GD, Linnstaedt SD, Rauch SL, Storrow AB, Lewandowski C, Musey PI, Hendry PL, Sheikh S, Jones CW, Punches BE, Swor RA, Hudak LA, Pascual JL, Seamon MJ, Harris E, Pearson C, Peak DA, Merchant RC, Domeier RM, Rathlev NK, O'Neil BJ, Sergot P, Sanchez LD, Bruce SE, Kessler RC, Koenen KC, McLean SA, Bucci V, Haran JP. Association between microbiome and the development of adverse posttraumatic neuropsychiatric sequelae after traumatic stress exposure. Transl Psychiatry. 2023 Nov 18; 13(1):354.

View in: PubMed
Mart?nez R, Mesas C, Guzm?n A, Galisteo M, L?pez-Jurado M, Prados J, Melguizo C, Berm?dez F, Porres JM. Bioavailability and biotransformation of linolenic acid from basil seed oil as a novel source of omega-3 fatty acids tested on a rat experimental model. Food Funct. 2022 Jul 18; 13(14):7614-7628.

View in: PubMed
Bourassa MW, Abrams SA, Beliz?n JM, Boy E, Cormick G, Quijano CD, Gibson S, Gomes F, Hofmeyr GJ, Humphrey J, Kraemer K, Lividini K, Neufeld LM, Palacios C, Shlisky J, Thankachan P, Villalpando S, Weaver CM. Interventions to improve calcium intake through foods in populations with low intake. Ann N Y Acad Sci. 2022 05; 1511(1):40-58.

View in: PubMed
Gao S, Siddiqui N, Etim I, Du T, Zhang Y, Liang D. Developing nutritional component chrysin as a therapeutic agent: Bioavailability and pharmacokinetics consideration, and ADME mechanisms. Biomed Pharmacother. 2021 Oct; 142:112080.

View in: PubMed
Du T, Sun R, Etim I, Zheng Z, Liang D, Hu M, Gao S. Age-and Region-Dependent Disposition of Raloxifene in Rats. Pharm Res. 2021 Aug; 38(8):1357-1367.

View in: PubMed
Awosemo O, Neelakantan H, Watowich S, Ma J, Wu L, Chow DS, Liang D. Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. J Pharm Biomed Anal. 2021 Sep 10; 204:114255.

View in: PubMed
Gupta R, Chen Y, Xie H. In vitro dissolution considerations associated with nano drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 11; 13(6):e1732.

View in: PubMed
Patel P, Pol A, Kalaria D, Date AA, Kalia Y, Patravale V. Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy. Eur J Pharm Biopharm. 2021 Aug; 165:66-74.

View in: PubMed
Adekiya TA, Kumar P, Kondiah PPD, Pillay V, Choonara YE. Synthesis and therapeutic delivery approaches for praziquantel: a patent review (2010-present). Expert Opin Ther Pat. 2021 Sep; 31(9):851-865.

View in: PubMed

People

Explore

Similar Concepts

Top Journals